Prader-Willi Syndrome (PWS) is a multisystem defect characterized by obesity, hypogenitalism and short stature for genetic background. Low GH serum levels have been found in patients with PWS and were related to a hypothalamic-pituitary dysfunction. We studied spontaneous nocturnal GH secretion and GH-response to provocative tests in five patients affected by PWS. We observed in three of them (Group A) abnormally low GH and IGF-1 serum levels. In the other two patients (Group B) GH secretion and IGF-1 serum levels were normal. In all patients no thyroid dysfunction was observed. These data might suggest the presence of two different subgroups of patients affected by PWS, from an endocrinological point of view. An abnormally low GH secretion would be evident only in a subgroup of patients, which appears to be normal in the remaining patients. This casistic is small in number, but if our data will be confirmed by more extensive studies it may be possible to identify a specific population of PWS patients who could benefit from recombinant GH- therapy. (J. Endocrinol. Invest. 21: 418-422, 1998) (C)1998, Editrice Kurtis

Grosso, S., Cioni, M., Buoni, S., Peruzzi, L., Pucci, L., Berardi, R. (1988). Growth hormone secretion in Prader-Willi syndrome. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 21(7), 418-422 [10.1007/BF03347319].

Growth hormone secretion in Prader-Willi syndrome

Grosso, S.;Cioni, M.;Buoni, S.;Berardi, R.
1988-01-01

Abstract

Prader-Willi Syndrome (PWS) is a multisystem defect characterized by obesity, hypogenitalism and short stature for genetic background. Low GH serum levels have been found in patients with PWS and were related to a hypothalamic-pituitary dysfunction. We studied spontaneous nocturnal GH secretion and GH-response to provocative tests in five patients affected by PWS. We observed in three of them (Group A) abnormally low GH and IGF-1 serum levels. In the other two patients (Group B) GH secretion and IGF-1 serum levels were normal. In all patients no thyroid dysfunction was observed. These data might suggest the presence of two different subgroups of patients affected by PWS, from an endocrinological point of view. An abnormally low GH secretion would be evident only in a subgroup of patients, which appears to be normal in the remaining patients. This casistic is small in number, but if our data will be confirmed by more extensive studies it may be possible to identify a specific population of PWS patients who could benefit from recombinant GH- therapy. (J. Endocrinol. Invest. 21: 418-422, 1998) (C)1998, Editrice Kurtis
Grosso, S., Cioni, M., Buoni, S., Peruzzi, L., Pucci, L., Berardi, R. (1988). Growth hormone secretion in Prader-Willi syndrome. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 21(7), 418-422 [10.1007/BF03347319].
File in questo prodotto:
File Dimensione Formato  
Growth hormone secretion in Prader-Willi syndrome.pdf

non disponibili

Tipologia: PDF editoriale
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 526.66 kB
Formato Adobe PDF
526.66 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/1000510
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo